logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Ginkgo Bioworks Completes Acquisition Of Zymergen

Oct 19, 2022•about 3 years ago

Acquiring Company

Ginkgo Bioworks

Acquired Company

Zymergen

BostonEmeryvilleSustainabilityScience And EngineeringSoftwareBiotechnologyManufacturing

Description

Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches.

Company Information

Company

Ginkgo Bioworks

Location

Boston, Massachusetts, United States

About

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed